Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors

Nature Medicine

Volumn 10, Issue 12, 2004, Pages 1321-1328

  Issaeva, Natalia ^a   Bozko, Przemyslaw ^a   Enge, Martin ^a   Protopopova, Marina ^a   Verhoef, Lisette G G C ^a   Masucci, Maria ^a   Pramanik, Aladdin ^b   Selivanova, Galina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HUMAN DOUBLE MINUTE 2 PROTEIN; PROTEIN; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLAST; MOLECULAR SIZE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TREATMENT OUTCOME; TUMOR; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FURANS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYMPHOCYTES; MICE; NUCLEAR PROTEINS; PLASMIDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 11144315535     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1146     Document Type: Article

References (46)

1. Vogelstein, B., Lane, D. & Levine, A.J. Surfing the p53 network. Nature 408, 307-310 (2000).
2. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614 (2002).
3. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3, 102-109 (2003).
4. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 5-8 (1998).
5. Montes de Oca Luna, R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
6. Vousden, K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602, 47-59.(2002).
7. Evan, G. & Littlewood, T. A matter of life and cell death. Science 281, 1317-1322 (1998).
8. Bottger, A. et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860-869 (1997).
9. Chene, P. et al. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 299, 245-253 (2000).
10. Midgley, C.A. et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19, 2312-2323 (2000).
11. Lai, Z. et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. USA 99, 14734-14739 (2002).
12. Zhao, J. et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69-77 (2002).
13. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
14. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998).
15. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
16. Rigler, R. et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc. Natl. Acad. Sci. USA 96, 13318-13323 (1999).
17. Yakovleva, T. et al. p53 Latency. C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences. J. Biol. Chem. 276, 15650-15658 (2001).
18. Wang, L., Grossman, S.R. & Kieff, E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc. Natl. Acad. Sci. USA 97, 430-435 (2000).
19. Lin, J., Chen, J., Elenbaas, B. & Levine, A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kDa protein. Genes Dev. 8, 1235-1246 (1994).
20. Kussie, P.H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953. (1996).
21. Burch, L.R., Midgley, C.A., Currie, R.A., Lane, D.P. & Hupp, T.R. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett. 472, 93-98 (2000).
22. Kanovsky, M. et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl. Acad. Sci. USA 98, 12438-12443 (2001).
23. Gu, W. & Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
24. Grossman, S.R. et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344 (2003).
25. Bergamaschi, D. et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33, 162-167 (2003).
26. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577-590 (2003).
27. Nikolaev, A.Y., Li, M., Puskas, N., Qin, J. & Gu, W. Parc: a cytoplasmic anchor for p53. Cell 112, 29-40 (2003).
28. Pandhare, J., Dash, C., Rao, M. & Deshpande, V. Slow tight binding inhibition of proteinase K by a proteinaceous inhibitor: conformational alterations responsible for conferring irreversibility to the enzyme-inhibitor complex. J. Biol. Chem. 278, 48735-48744 (2003).
29. Jabbur, J.R. et al. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 21, 7100-7113 (2002).
30. Iyer, N.G. et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc. Natl. Acad. Sci. USA 101, 7386-7391 (2004).
31. Grossman, S.R. et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2, 405-415 (1998).
32. Liu, W.U., Midgley, C., Stephen, C., Saville, M. & Lane, D.P. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. J. Mol. Biol. 313, 711-731 (2001).
33. Friedlander, P., Legros, Y., Soussi, T. & Prives, C. Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem. 271, 25468-25478 (1996).
34. Hansen, S., Hupp, T.R. & Lane, D.P. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. J. Biol. Chem. 271, 3917-3924 (1996).
35. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
36. Jeffrey, P.D., Gorina, S. & Pavletich, N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498-14502 (1995).
37. Lee, W. et al. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1, 877-890 (1994).
38. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915 (1990).
39. D'Orazi, G. et al. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J. Gene Med. 2, 11-21 (2000).
40. Nieves-Neira, W. et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol. Pharmacol. 56, 478-484 (1999).
41. Rivera, M.I. et al. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem. Pharmacol. 57, 1283-1295 (1999).
42. Selivanova, G. et al. The single-stranded DNA end binding site of p53 coincides with the C- terminal regulatory region. Nucleic Acids Res. 24, 3560-3567 (1996).
43. Schuhmacher, M. et al. Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. 9, 1255-1258 (1999).
44. Felsher, D.W. & Bishop, J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA 96, 3940-3944 (1999).
45. Vigo, E. et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell. Biol. 19, 6379-6395 (1999).
46. Hengstermann, A., Linares, L.K., Ciechanover, A., Whitaker, N.J. & Scheffner, M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. USA 98, 1218-1223 (2001).